Abstract
The ability of the thyroid to accumulate iodide provides the basis for radioiodine ablation of differentiated thyroid cancers and their metastases. Most thyroid tumours exhibit reduced iodide uptake, although the mechanisms accounting for this remain poorly understood. Pituitary tumour transforming gene (PTTG) is a proto-oncogene implicated in the pathogenesis of thyroid tumours. We now show that PTTG and its binding factor PBF repress expression of sodium iodide symporter (NIS) messenger RNA (mRNA), and inhibit iodide uptake. This process is mediated at least in part through fibroblast growth factor-2. In detailed studies of the NIS promoter in rat FRTL-5 cells, PTTG and PBF demonstrated specific inhibition of promoter activity via the human upstream enhancer element (hNUE). Within this ∼1 kb element, a complex PAX8-upstream stimulating factor 1 (USF1) response element proved critical both to basal promoter activity and to PTTG and PBF repression of NIS. In particular, repression by PTTG was contingent upon the USF1, but not the PAX8, site. Finally, in human primary thyroid cells, PTTG and PBF similarly repressed the NIS promoter via hNUE. Taken together, our data suggest that the reported overexpression of PTTG and PBF in differentiated thyroid cancer has profound implications for activity of the NIS gene, and hence significantly impacts upon the efficacy of radioiodine treatment.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ambesi-Impiombato FS, Parks LA, Coon HG . (1980). Culture of hormone-dependent functional epithelial cells from rat thyroids. Proc Natl Acad Sci USA 77: 3455–3459.
Arturi F, Russo D, Bidart JM, Scarpelli D, Schlumberger M, Filetti S . (2001). Expression pattern of the pendrin and sodium/iodide symporter genes in human thyroid carcinoma cell lines and human thyroid tumors. Eur J Endocrinol 145: 129–135.
Arturi F, Russo D, Giuffrida D, Schlumberger M, Filetti S . (2000). Sodium-iodide symporter (NIS) gene expression in lymph-node metastases of papillary thyroid carcinomas. Eur J Endocrinol 143: 623–627.
Behr M, Schmitt TL, Espinoza CR, Loos U . (1998). Cloning of a functional promoter of the human sodium/iodide-symporter gene. Biochem J 331 (Pt 2): 359–363.
Boelaert K, Franklyn JA . (2003). Sodium iodide symporter: a novel strategy to target breast, prostate, and other cancers? Lancet 361: 796–797.
Boelaert K, McCabe CJ, Tannahill LA, Gittoes NJ, Holder RL, Watkinson JC et al. (2003a). Pituitary tumor transforming gene and fibroblast growth factor-2 expression: potential prognostic indicators in differentiated thyroid cancer. J Clin Endocrinol Metab 88: 2341–2347.
Boelaert K, Tannahill LA, Bulmer JN, Kachilele S, Chan SY, Gittoes NJL et al. (2003b). A potential role for PTTG/securin in the developing human fetal brain. FASEB J 17: 1631–1639.
Boelaert K, Yu R, Tannahill LA, Stratford AL, Khanim FL, Eggo MC et al. (2004). PTTG's C-terminal PXXP motifs modulate critical cellular processes in vitro. J Mol Endocrinol 33: 663–677.
Caillou B, Troalen F, Baudin E, Talbot M, Filetti S, Schlumberger M et al. (1998). Na+/I- symporter distribution in human thyroid tissues: an immunohistochemical study. J Clin Endocrinol Metab 83: 4102–4106.
Castro MR, Bergert ER, Beito TG, Roche PC, Ziesmer SC, Jhiang SM et al. (1999). Monoclonal antibodies against the human sodium iodide symporter: utility for immunocytochemistry of thyroid cancer. J Endocrinol 163: 495–504.
Chien W, Pei L . (2000). A novel binding factor facilitates nuclear translocation and transcriptional activation function of the pituitary tumor-transforming gene product. J Biol Chem 275: 19422–19427.
Chun JT, Di DV, D'Andrea B, Zannini M, Di Lauro R . (2004). The CRE-like element inside the 5′-upstream region of the rat sodium/iodide symporter gene interacts with diverse classes of b-Zip molecules that regulate transcriptional activities through strong synergy with Pax-8. Mol Endocrinol 18: 2817–2829.
Cocks HC, Thompson S, Turner FE, Logan A, Franklyn JA, Watkinson JC et al. (2003). Role and regulation of the fibroblast growth factor axis in human thyroid follicular cells. Am J Physiol Endocrinol Metab 285: E460–E469.
Dai G, Levy O, Carrasco N . (1996). Cloning and characterization of the thyroid iodide transporter. Nature 379: 458–460.
Dohan O, De LV, Paroder V, Riedel C, Artani M, Reed M et al. (2003). The sodium/iodide symporter (NIS): characterization, regulation, and medical significance. Endocr Rev 24: 48–77.
Dominguez A, Ramos-Morales F, Romero F, Rios RM, Dreyfus F, Tortolero M et al. (1998). hPTTG, a human homologue of rat PTTG, is overexpressed in hematopoietic neoplasms. Evidence for a transcriptional activation function of hPTTG. Oncogene 17: 2187–2193.
Eggo MC, Hopkins JM, Franklyn JA, Johnson GD, Sanders DS, Sheppard MC . (1995). Expression of fibroblast growth factors in thyroid cancer. J Clin Endocrinol Metab 80: 1006–1011.
Eggo MC, King WJ, Black EG, Sheppard MC . (1996). Functional human thyroid cells and their insulin-like growth factor- binding proteins: regulation by thyrotropin, cyclic 3′,5′ adenosine monophosphate, and growth factors. J Clin Endocrinol Metab 81: 3056–3062.
Heaney AP, Nelson V, Fernando M, Horwitz G . (2001). Transforming events in thyroid tumorigenesis and their association with follicular lesions. J Clin Endocrinol Metab 86: 5025–5032.
Heaney AP, Singson R, McCabe CJ, Nelson V, Nakashima M, Melmed S . (2000). Expression of pituitary-tumour transforming gene in colorectal tumours. Lancet 355: 716–719.
Ishikawa H, Heaney AP, Yu R, Horwitz GA, Melmed S . (2001). Human pituitary tumor-transforming gene induces angiogenesis. J Clin Endocrinol Metab 86: 867–874.
Jhiang SM, Cho JY, Ryu KY, DeYoung BR, Smanik PA, McGaughy VR et al. (1998). An immunohistochemical study of Na+/I- symporter in human thyroid tissues and salivary gland tissues. Endocrinology 139: 4416–4419.
Kim DS, Franklyn JA, Boelaert K, Eggo MC, Watkinson JC, McCabe CJ . (2006). Pituitary tumor transforming gene (PTTG) stimulates thyroid cell proliferation via a vascular endothelial growth factor/kinase insert domain receptor/inhibitor of DNA binding-3 autocrine pathway. J Clin Endocrinol Metab 91: 4603–4611.
Kim DS, Pemberton H, Stratford AL, Buelaert K, Watkinson JC, Lopes V et al. (2005). Pituitary tumour transforming gene (PTTG) induces genetic instability in thyroid cells. Oncogene 24: 4861–4866.
Kogai T, Endo T, Saito T, Miyazaki A, Kawaguchi A, Onaya T . (1997). Regulation by thyroid-stimulating hormone of sodium/iodide symporter gene expression and protein levels in FRTL-5 cells. Endocrinology 138: 2227–2232.
Kogai T, Schultz JJ, Johnson LS, Huang M, Brent GA . (2000). Retinoic acid induces sodium/iodide symporter gene expression and radioiodide uptake in the MCF-7 breast cancer cell line. Proc Natl Acad Sci USA 97: 8519–8524.
Lazar V, Bidart JM, Caillou B, Mahe C, Lacroix L, Filetti S et al. (1999). Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab 84: 3228–3234.
Lin X, Ryu KY, Jhiang SM . (2004). Cloning of the 5′-flanking region of mouse sodium/iodide symporter and identification of a thyroid-specific and TSH-responsive enhancer. Thyroid 14: 19–27.
Liou MJ, Lin JD, Chan EC, Liu FH, Chao TC, Weng HF . (2000). Detection of mRNA of sodium iodide symporter in benign and malignant human thyroid tissues. Cancer Lett 160: 75–80.
McCabe CJ, Boelaert K, Tannahill LA, Heaney AP, Stratford AL, Khaira JS et al. (2002). Vascular endothelial growth factor (VEGF), its receptor KDR and pituitary tumor transforming gene in pituitary tumors. J Clin Endocrinol Metab 87: 4238–4244.
McCabe CJ, Khaira JS, Boelaert K, Heaney AP, Tannahill LA, Hussain S et al. (2003). Expression of pituitary tumour transforming gene (PTTG) and fibroblast growth factor-2 (FGF-2) in human pituitary adenomas: relationships to clinical tumour behaviour. Clin Endocrinol (Oxford) 58: 141–150.
McCabe CJ . (2001). Genetic targets for the treatment of pituitary adenomas – focus on the pituitary tumor transforming gene. Curr Opinion Pharmacol 1: 620–625.
Park HJ, Kim JY, Park KY, Gong G, Hong SJ, Ahn IM . (2000). Expressions of human sodium iodide symporter mRNA in primary and metastatic papillary thyroid carcinomas. Thyroid 10: 211–217.
Pei L, Melmed S . (1997). Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol 11: 433–441.
Pei L . (2000). Activation of mitogen-activated protein kinase cascade regulates pituitary tumor-transforming gene transactivation function. J Biol Chem 275: 31191–31198.
Pei L . (2001). Identification of c-myc as a down-stream target for pituitary tumor-transforming gene. J Biol Chem 276: 8484–8491.
Puri R, Tousson A, Chen L, Kakar SS . (2001). Molecular cloning of pituitary tumor transforming gene 1 from ovarian tumors and its expression in tumors. Cancer Lett 163: 131–139.
Ramsden JD, Cocks HC, Shams M, Nijjar S, Watkinson JC, Sheppard MC et al. (2001). Tie-2 is expressed on thyroid follicular cells, is increased in goiter, and is regulated by thyrotropin through cyclic adenosine 3′,5′-monophosphate. J Clin Endocrinol Metab 86: 2709–2716.
Ringel MD, Anderson J, Souza SL, Burch HB, Tambascia M, Shriver CD, Tuttle Reuben Maitland. (2001). Expression of the sodium iodide symporter and thyroglobulin genes are reduced in papillary thyroid cancer. Mod Pathol 14: 289–296.
Romero F, Multon MC, Ramos-Morales F, Dominguez A, Bernal JA, Pintor-Toro JA et al. (2001). Human securin, hPTTG, is associated with Ku heterodimer, the regulatory subunit of the DNA-dependent protein kinase. Nucleic Acids Res 29: 1300–1307.
Ryu KY, Senokozlieff ME, Smanik PA, Wong MG, Siperstein AE, Duh QY et al. (1999). Development of reverse transcription-competitive polymerase chain reaction method to quantitate the expression levels of human sodium iodide symporter. Thyroid 9: 405–409.
Ryu KY, Tong Q, Jhiang SM . (1998). Promoter characterization of the human Na+/I- symporter. J Clin Endocrinol Metab 83: 3247–3251.
Saez C, Martinez-Brocca MA, Castilla C, Soto A, Navarro E, Tortolero M et al. (2006). Prognostic significance of hPTTG immunohistochemical expression in differentiated thyroid cancer. J Clin Endocrinol Metab 91: 1404–1409.
Saito T, Endo T, Kawaguchi A, Ikeda M, Katoh R, Kawaoi A et al. (1998). Increased expression of the sodium/iodide symporter in papillary thyroid carcinomas. J Clin Invest 101: 1296–1300.
Schmitt TL, Espinoza CR, Loos U . (2001). Transcriptional regulation of the human sodium/iodide symporter gene by Pax8 and TTF-1. Exp Clin Endocrinol Diabetes 109: 27–31.
Shibata Y, Haruki N, Kuwabara Y, Nishiwaki T, Kato J, Shinoda N et al. (2002). Expression of PTTG (pituitary tumor transforming gene) in esophageal cancer. Jpn J Clin Oncol 32: 233–237.
Smanik PA, Liu Q, Furminger TL, Ryu K, Xing S, Mazzaferri EL et al. (1996). Cloning of the human sodium lodide symporter. Biochem Biophys Res Commun 226: 339–345.
Smanik PA, Ryu KY, Theil KS, Mazzaferri EL, Jhiang SM . (1997). Expression, exon-intron organization, and chromosome mapping of the human sodium iodide symporter. Endocrinology 138: 3555–3558.
Spitzweg C, Joba W, Morris JC, Heufelder AE . (1999). Regulation of sodium iodide symporter gene expression in FRTL-5 rat thyroid cells. Thyroid 9: 821–830.
Stratford AL, Boelaert K, Tannahill LA, Kim DS, Warfield A, Eggo MC et al. (2005). Pituitary tumor transforming gene binding factor: a novel transforming gene in thyroid tumorigenesis. J Clin Endocrinol Metab 90: 4341–4349.
Taki K, Kogai T, Kanamoto Y, Hershman JM, Brent GA . (2002). A thyroid-specific far-upstream enhancer in the human sodium/iodide symporter gene requires Pax-8 binding and cyclic adenosine 3′,5′-monophosphate response element-like sequence binding proteins for full activity and is differentially regulated in normal and thyroid cancer cells. Mol Endocrinol 16: 2266–2282.
Tanaka K, Otsuki T, Sonoo H, Yamamoto Y, Udagawa K, Kunisue H et al. (2000). Semi-quantitative comparison of the differentiation markers and sodium iodide symporter messenger ribonucleic acids in papillary thyroid carcinomas using RT–PCR. Eur J Endocrinol 142: 340–346.
Yaspo ML, Aaltonen J, Horelli-Kuitunen N, Peltonen L, Lehrach H . (1998). Cloning of a novel human putative type Ia integral membrane protein mapping to 21q22.3. Genomics 49: 133–136.
Yu R, Melmed S . (2001). Oncogene activation in pituitary tumors. Brain Pathol 11: 328–341.
Yu R, Ren SG, Horwitz GA, Wang Z, Melmed S . (2000). Pituitary tumor transforming gene (PTTG) regulates placental JEG-3 cell division and survival: evidence from live cell imaging. Mol Endocrinol 14: 1137–1146.
Zhang X, Horwitz GA, Heaney AP, Nakashima M, Prezant TR, Bronstein MD et al. (1999a). Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab 84: 761–767.
Zhang X, Horwitz GA, Prezant TR, Valentini A, Nakashima M, Bronstein MD et al. (1999b). Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). Mol Endocrinol 13: 156–166.
Zou H, McGarry TJ, Bernal T, Kirschner MW . (1999). Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science 285: 418–422.
Zur A, Brandeis M . (2001). Securin degradation is mediated by fzy and fzr, and is required for complete chromatid separation but not for cytokinesis. EMBO J 20: 792–801.
Acknowledgements
This work was supported by the Wellcome Trust, the Medical Research Council (UK), the Endowment Fund of the Former United Birmingham Hospitals and the Marjorie Robinson Fund. We thank Dr John Morris (Mayo Clinic, Rochester, USA) and Dr Nancy Carrasco (Albert Einstein College of Medicine, New York, USA) for the provision of NIS antibodies, and we acknowledge Roger Holder, Department of Statistics, University of Birmingham, for statistical advice.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Boelaert, K., Smith, V., Stratford, A. et al. PTTG and PBF repress the human sodium iodide symporter. Oncogene 26, 4344–4356 (2007). https://doi.org/10.1038/sj.onc.1210221
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1210221
Keywords
This article is cited by
-
Genomic alterations in thyroid cancer: biological and clinical insights
Nature Reviews Endocrinology (2024)
-
Advances in the molecular mechanism and targeted therapy of radioactive-iodine refractory differentiated thyroid cancer
Medical Oncology (2023)
-
PTTG1-interacting protein (PTTG1IP/PBF) predicts breast cancer survival
BMC Cancer (2017)
-
Modulation of Sodium Iodide Symporter in Thyroid Cancer
Hormones and Cancer (2014)